Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.19)
# 2,917
Out of 5,008 analysts
113
Total ratings
38.61%
Success rate
-1.48%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANVS Annovis Bio | Maintains: Buy | $17 | $2.26 | +652.21% | 4 | Sep 30, 2025 | |
| CLNN Clene | Maintains: Buy | $83 → $48 | $9.62 | +398.96% | 6 | Aug 18, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $15 | $6.67 | +124.89% | 4 | Aug 1, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $9.50 | +184.21% | 6 | Jul 29, 2025 | |
| ATAI Atai Life Sciences | Maintains: Buy | $12 → $11 | $5.57 | +97.49% | 3 | Jul 28, 2025 | |
| CYBN Cybin | Maintains: Buy | $73 → $70 | $6.27 | +1,017.32% | 8 | Jul 8, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $158 → $160 | $139.30 | +14.86% | 16 | May 6, 2025 | |
| BIIB Biogen | Maintains: Buy | $265 → $220 | $151.49 | +45.22% | 21 | May 2, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $10.50 | +138.10% | 6 | Mar 13, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 → $12 | $5.26 | +128.14% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $2.65 | +2,918.87% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $13.22 | +111.80% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $12.84 | +9.03% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $31.73 | -36.97% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $21.31 | +54.86% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $15.55 | +864.63% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $20.30 | - | 2 | Jan 31, 2017 |
Annovis Bio
Sep 30, 2025
Maintains: Buy
Price Target: $17
Current: $2.26
Upside: +652.21%
Clene
Aug 18, 2025
Maintains: Buy
Price Target: $83 → $48
Current: $9.62
Upside: +398.96%
COMPASS Pathways
Aug 1, 2025
Maintains: Buy
Price Target: $15
Current: $6.67
Upside: +124.89%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $9.50
Upside: +184.21%
Atai Life Sciences
Jul 28, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $5.57
Upside: +97.49%
Cybin
Jul 8, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $6.27
Upside: +1,017.32%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $158 → $160
Current: $139.30
Upside: +14.86%
Biogen
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $151.49
Upside: +45.22%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $10.50
Upside: +138.10%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $5.26
Upside: +128.14%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $2.65
Upside: +2,918.87%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $13.22
Upside: +111.80%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $12.84
Upside: +9.03%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $31.73
Upside: -36.97%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $21.31
Upside: +54.86%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $15.55
Upside: +864.63%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $20.30
Upside: -